-
Mashup Score: 0New Collaborative Guideline Highlights the Importance of Multidisciplinary Care for Patients With Osteoradionecrosis - 20 hour(s) ago
A joint International Society of Oral Oncology-Multinational Association for Supportive Care in Cancer and ASCO guideline seeks to fill a gap in the clinical guidance for patients with head and neck cancers who develop osteoradionecrosis following their head and neck radiation.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 60Selecting First-Line Therapy for Metastatic Urothelial Carcinoma: Does ‘One Size Fit All’ or Is Customization Needed? - 1 day(s) ago
Enfortumab vedotin/pembrolizumab, gemcitabine-cisplatin/nivolumab, and the JAVELIN paradigm can all play a role as first-line therapy for appropriately selected patients with advanced urothelial carcinoma.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 107ctDNA Assays: Exploring Their Clinical Use in Oncology Care - 1 day(s) ago
ctDNA assays are quickly finding their way into the clinic. These assays have a potential role to play in all phases of the cancer continuum because they answer various clinical questions (Figure 1). Their use is moving up to earlier-stage settings from their initial development and approval for patients with metastatic cancer. As these agents enter more prominent clinical use, it is vital for clinicians to understand that there are different kinds of ctDNA assays.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 12Glecirasib Demonstrates Encouraging Efficacy and Safety in KRASG12C-Mutated NSCLC in Phase 2 Trial From China - 2 day(s) ago
Data from a single-arm phase 2 trial conducted in China showed that glecirasib produced a response rate of 48% in patients with advanced KRASG12C-mutated NSCLC when used in the second- or later-line setting.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 14
Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for patients and the role of surgery in the era of targeted therapy and immuno-oncology in lung cancer.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 20
Cancer cachexia-anorexia is a major clinical problem. Investigational new drugs, mainly aimed at the regulation of appetite and satiety in the hypothalamus/brainstem, are in development to address this critical issue.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Cancer cachexia–anorexia is a major clinical problem in patients w/ advanced cancers. Although there is high interest in restoring appetite to these patients, challenges related to the determination of efficacy remain. https://t.co/GKuwtCDI4f @UAlberta @MayoClinic #ASCODailyNews https://t.co/5Y00OvpICe
-
-
Mashup Score: 13
Doctors James Ferriss, Linda Duska, and Jayanthi Lea discuss the promise and the challenges of targeting the immune system with immune checkpoint inhibitors, or ICIs, in cervical and endometrial cancers. They also examine emerging data that support the use of ICIs in recurrent cervical cancer, the potential for curing some patients with advanced endometrial cancer, and molecular factors that make cervical cancer a good target for immunotherapy.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🎙️ Dr. James Ferriss of @HopkinsMedicine, @Lduska of @MedicineUVA & Dr. Jayanthi Lea of @UTSWMedCenter discuss the promise — & the challenges — of immunotherapy in cervical & endometrial cancers on the latest episode of the #ASCODailyNews Podcast: https://t.co/f5KZKeJwMp #gyncsm https://t.co/rEgJFUAOhU
-
-
Mashup Score: 4Idecabtagene Vicleucel in Early Relapsed/Refractory Myeloma: Is There an Efficacy Benefit? - 14 day(s) ago
Early administration ide-cel in relapsed/refractory multiple myeloma is crucial for achieving deeper responses and should not be delayed; however, logistics and product availability remain critical components.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12
Drs. Shaalan Beg and Aparna Parikh discuss the role of ctDNA as a powerful prognostic biomarker for GI cancers, along with its impact on risk stratification and the detection of recurrence. They highlight key studies in ctDNA that were featured at the 2024 ASCO GI Cancers Symposium, including COBRA, GALAXY, and BESPOKE in CRC, as well as the promise of ctDNA testing in the preoperative detection of iCCA.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
🎙️ @ShaalanBeg of @Science37x and @aparna1024 of @MGHCancerCenter discuss the promise of #ctDNA as a prognostic biomarker to improve risk stratification, detect recurrence, and inform adjuvant therapy in GI cancers on the #ASCODailyNews Podcast: https://t.co/osirPSIMWh #gicsm https://t.co/qedwsOTREx
-
-
Mashup Score: 55Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy - 28 day(s) ago
Current research efforts in early-stage NSCLC have expanded to explore the efficacy of targeted therapy in patients with oncogenic driver mutations beyond EGFR and ALK.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
Collaborative efforts between @isooworld @CancerCareMASCC and ASCO have results in new consensus-based guidance on the prevention & management of osteoradionecrosis in pts w/ head & neck cancers treated w/ radiation therapy. #ASCODailyNews has more: https://t.co/k0xxpz0EBq